Know More About This Test

PAPP-A is a protein produced by the placenta during pregnancy. Measurement of PAPP-A levels in maternal blood during the first trimester is an essential component of prenatal screening for chromosomal abnormalities, particularly Down syndrome.

Low PAPP-A levels may also be associated with adverse pregnancy outcomes such as preeclampsia or fetal growth restriction, helping guide closer monitoring for better maternal and fetal health.

Why Is This Test Recommended?

This test is recommended for pregnant women between 11 and 13 weeks of gestation as part of first-trimester combined screening, often alongside nuchal translucency ultrasound and other markers to assess overall risk for genetic conditions and pregnancy complications.

What Do the Results Indicate?

Low PAPP-A levels may indicate increased risk of chromosomal abnormalities like trisomy 21 or placental dysfunction leading to issues like low birth weight. Normal levels suggest lower risk, but results are always interpreted with other screening elements for a comprehensive view.

How Is the Test Performed and Prepared For?

• A blood sample is collected via a simple venipuncture from the arm, typically during a routine prenatal visit, with results available within days.

• No fasting is required, allowing for convenience, but accurate gestational age determination through early ultrasound is crucial for reliable interpretation.

• Discuss any medications or health conditions with your doctor beforehand to ensure the results align with your specific pregnancy profile.

Frequently Asked Questions (FAQs)

1. Is PAPP-A a diagnostic test?
   No, it's a screening tool only—PAPP-A measures placental protein to estimate risk but doesn't confirm conditions like Down syndrome. If results show elevated risk, diagnostic tests like amniocentesis or CVS are offered for definitive answers, allowing informed decisions without unnecessary procedures.
   

2. Can results be false positive?
   Yes, false positives can occur due to factors like maternal age, smoking, or multiple pregnancies, leading to unnecessary anxiety. That's why PAPP-A is combined with ultrasound and other markers for better accuracy; about 5% of screenings flag high risk, but most are false alarms—follow-up counseling helps clarify next steps.
   

3. Is ultrasound also required?
   Yes, ultrasound is essential as part of the combined first-trimester screening, measuring nuchal translucency (fluid at the baby's neck) alongside PAPP-A and hCG levels. This duo provides a more precise risk assessment than blood tests alone, typically performed in the same visit for efficiency.
   

4. Does low PAPP-A harm the baby?
   Risk marker only—low PAPP-A signals potential issues like growth restriction but doesn't directly harm the baby; it prompts increased monitoring such as extra ultrasounds or blood pressure checks to catch and manage problems early, often resulting in healthy outcomes with proper care.
   

5. Is repeat testing needed?
   Not usually, as PAPP-A is a one-time first-trimester screen with stable placental production; repeats aren't standard unless new concerns arise later in pregnancy. If initial results are borderline, your doctor may suggest additional non-invasive tests like cell-free DNA analysis for reassurance.